Byetta exenatide regulatory update

The European Commission approved an expanded label for Byetta exenatide from Amylin to include adjunctive therapy to basal insulin for Type II diabetes with or without metformin and/or Actos pioglitazone in adults who have not achieved adequate glycemic control with the agents. The synthetic exendin-4 is marketed in Europe for Type II diabetes mellitus in combination with metformin, a sulphonylurea or a thiazolidinedione; metformin plus a sulphonylurea; or metformin plus thiazolidinedione in patients who have not achieved adequate glycemic control on these oral therapies. ...